# Centers for Disease Control and Prevention Model Performance Evaluation Program T-Lymphocyte Immunophenotyping (TLI) 

Figures and Tables Used for the Analysis of Participant Laboratory Results for the

September 1995 Shipment

## U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service
Centers for Disease Control and Prevention
Public Health Practice Program Office
Division of Laboratory Systems
Atlanta, Georgia 30333

Use of trade names is for identification only and does not constitute endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 12, 1995 TLI Shipment Specimens 

| Panel <br> Letter | Participant Lab Vial Label | CDC Donor <br> Number | Donor Information <br> (HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count) |
| :---: | :---: | :---: | :---: |
| A | A1, A5 | 01 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | A2 | 08 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | A3 | 12 | HIV-1 Antibody-Negative |
|  | A4 | 13 | HIV-1 Antibody-Negative |
| B | B1 | 09 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | B2 | 13 | HIV-1 Antibody-Negative |
|  | B3, B4 | 02 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | B5 | 14 | HIV-1 Antibody-Negative |
| C | C1, C2 | 03 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | C3 | 15 | HIV-1 Antibody-Negative |
|  | C4 | 12 | HIV-1 Antibody-Negative |
|  | C5 | 10 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
| D | D1 | 12 | HIV-1 Antibody-Negative |
|  | D2, D4 | 04 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | D3 | 08 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | D5 | 13 | HIV-1 Antibody-Negative |
| E | E1 | 13 | HIV-1 Antibody-Negative |
|  | E2 | 15 | HIV-1 Antibody-Negative |
|  | E3 | 09 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | E4, E5 | 05 | HIV-1 Antibody-Positive, $\mathrm{CD}^{+}$count $\geq 500$ |
| F | F1 | 14 | HIV-1 Antibody-Negative |
|  | F2, F3 | 06 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | F4 | 10 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | F5 | 12 | HIV-1 Antibody-Negative |
| G | G1 | 14 | HIV-1 Antibody-Negative |
|  | G2, G4 | 07 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | G3 | 15 | HIV-1 Antibody-Negative |
|  | G5 | 11 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |

[^0]
# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 19, 1995 TLI Shipment Specimens 

| Panel | Participant Lab | CDC Donor |
| :--- | :---: | :---: |
| Letter | Vial Label | Number |

## Donor Information <br> (HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count)

| H | H1 | 24 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
| :---: | :---: | :---: | :---: |
|  | H2 | 29 | HIV-1 Antibody-Negative |
|  | H3, H5 | 17 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | H4 | 28 | HIV-1 Antibody-Negative |
| I | I1, I4 | 18 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | I2 | 27 | HIV-1 Antibody-Negative |
|  | I3 | 25 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | I5 | 30 | HIV-1 Antibody-Negative |
| J | J1 | 23 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | J2 | 28 | HIV-1 Antibody-Negative |
|  | J3, J5 | 19 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | J4 | 27 | HIV-1 Antibody-Negative |
| K | K1, K5 | 20 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | K2 | 24 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | K3 | 29 | HIV-1 Antibody-Negative |
|  | K4 | 28 | HIV-1 Antibody-Negative |
| L | L1 | 25 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | L2, L5 | 21 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | L3 | 27 | HIV-1 Antibody-Negative |
|  | L4 | 30 | HIV-1 Antibody-Negative |
| M | M1 | 23 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | M2 | 27 | HIV-1 Antibody-Negative |
|  | M3, M5 | 16 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | M4 | 28 | HIV-1 Antibody-Negative |
| N | N1, N4 | 22 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | N2 | 26 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | N3 | 29 | HIV-1 Antibody-Negative |
|  | N5 | 30 | HIV-1 Antibody-Negative |

${ }^{\text {a }}$ Human immunodeficiency virus type 1

# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 26, 1995 TLI Shipment Specimens 

| Panel | Participant Lab |
| :--- | :---: |
| Letter | Vial Label |


| O | O 1 | 44 |
| :--- | :--- | :--- |
|  | $\mathrm{O} 2,03$ | 33 |
|  | O4 | 42 |
|  | O5 | 40 |
| P | $\mathrm{P} 1, \mathrm{P} 3$ | 34 |
|  | P 2 | 43 |
|  | P4 | 38 |
|  | P5 | 42 |
|  |  |  |
| Q | Q1 | 39 |
|  | Q2, Q4 | 35 |
|  | Q3 | 45 |
|  | Q5 | 43 |
| R | R1, R5 |  |
|  | R2 | 36 |
|  | R3 | 40 |
|  | R4 | 42 |
|  |  | 45 |

S S1, S5 31

S2

S4 38
$\begin{array}{lll}\mathrm{T} & \mathrm{T} 1 & 43\end{array}$
T2 39
T3, T4 32
T5 44

## CDC Donor <br> Number

44
33
42
40

34
43
38
42

39
35
45
43

36
40
42
45

31

## Donor Information <br> (HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count)

HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, $\mathrm{CD}^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative

Figure 1. Methods used to prepare specimens for T-lymphocyte immunophenotyping, reported by participant laboratories to CDC for the September 1995 shipment.


Figure 2. Methods used to fix specimens for T-lymphocyte immunophenotyping, reported by participant laboratories to CDC for the September 1995 shipment.


Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC DonorNumber -

| Cell Marker <br> (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 | H | $2-$ | H | 3 | H | 4 | H | 5 | H | 6 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >99 \\ 93 & -99 \\ & <93 \end{aligned}$ | $\begin{gathered} 3 \\ 27 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 82 & -100 \\ & <82 \end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 88 & -100 \\ & <88 \end{aligned}$ | $\begin{gathered} 0 \\ 27 \\ 1 \end{gathered}$ | $\begin{aligned} & >99 \\ 93 & -99 \\ & <93 \end{aligned}$ | $\begin{gathered} 1 \\ 24 \\ 3 \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ |
| CD14+ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0 \end{aligned}$ | $\begin{gathered} 2 \\ 26 \\ 0 \end{gathered}$ | $\begin{array}{r} >1 \\ 0 \\ 0 \end{array} \quad 1$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ | $\begin{array}{r} >3 \\ 0-3 \\ < \end{array}$ | $\begin{gathered} 0 \\ 28 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >0 \\ 0 & -0 \\ & <0 \end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 24 \\ 0 \end{gathered}$ | $\begin{array}{r} >5 \\ 0-5 \\ \\ <0 \end{array}$ | $\begin{gathered} 2 \\ 22 \\ 0 \end{gathered}$ |
| CD3+CD4+ | $\begin{aligned} & >46 \\ 40 & -46 \\ & <40 \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 1 \end{gathered}$ | $\begin{aligned} & >40 \\ 36 & -40 \\ & <36 \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \end{gathered}$ | $\begin{aligned} & >46 \\ 39 & -46 \\ & <39 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \end{gathered}$ | $\begin{aligned} & >30 \\ 23 & -30 \\ & <23 \end{aligned}$ | $\begin{gathered} 1 \\ 22 \\ 1 \end{gathered}$ | $\begin{aligned} & >51 \\ 46 & -51 \\ & <46 \end{aligned}$ | $\begin{gathered} 5 \\ 19 \\ 2 \end{gathered}$ | $\begin{aligned} & >39 \\ 30 & -39 \\ & <30 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ |
| CD3+CD8+ | $\begin{aligned} &>51 \\ & 45-51 \\ &<45 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} & >43 \\ 36 & -43 \\ & <36 \end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 2 \end{gathered}$ | $\begin{array}{r} >39 \\ 29 \end{array} \begin{array}{r} -39 \\ \\ <29 \\ \hline \end{array}$ | $\begin{gathered} 2 \\ 23 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>65 \\ & 54-65 \\ &<54 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>32 \\ & 24-32 \\ &<24 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 24 \\ 1 \end{gathered}$ | $\begin{aligned} &>57 \\ & 51-57 \\ &<51 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 4 \end{gathered}$ |
| CD3-CD19+ | $\begin{array}{r} >6 \\ 4-6 \\ <4 \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \end{gathered}$ | $\begin{aligned} & >10 \\ 8 & -10 \\ & <8 \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \end{gathered}$ | $\begin{aligned} & >12 \\ 7 & -12 \\ & <7 \end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 0 \end{gathered}$ | $\begin{array}{r} >5 \\ 1-5 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \end{gathered}$ | $\begin{aligned} & >14 \\ 9 & -14 \\ & <9 \end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \end{gathered}$ | $\begin{array}{r}  \\ > \\ 1-5 \\ 1 \end{array}$ | $\begin{gathered} 0 \\ 16 \\ 0 \end{gathered}$ |
| CD3-(CD56 \& CD16) + | $\begin{array}{r} >6 \\ 3-6 \\ <3 \end{array}$ | $\begin{gathered} 0 \\ 12 \\ 0 \end{gathered}$ | $\begin{array}{r} >9 \\ 2-9 \\ <2 \end{array}$ | $\begin{gathered} 0 \\ 16 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >13 \\ 5 & -13 \\ & <5 \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \end{gathered}$ | $\begin{array}{r} >7 \\ 2-7 \\ <2 \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \end{gathered}$ | $\begin{array}{r} >9 \\ 7-9 \\ <7 \end{array}$ | $\begin{gathered} 0 \\ 10 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >16 \\ 10 & -16 \\ & <10 \end{aligned}$ | 0 <br> 10 <br> 2 |
| CD3+Average | $\begin{aligned} & >92 \\ 87 & -92 \\ & <87 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \end{gathered}$ | $\begin{aligned} & >85 \\ 81 & -85 \\ & <81 \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \end{gathered}$ | $\begin{aligned} & >82 \\ 72 & -82 \\ & <72 \end{aligned}$ | $\begin{gathered} 0 \\ 27 \\ 1 \end{gathered}$ | $\begin{aligned} & >94 \\ 86 & -94 \\ & <86 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ | $\begin{aligned} & >81 \\ 75 & -81 \\ & <75 \end{aligned}$ | $\begin{gathered} 2 \\ 22 \\ 2 \end{gathered}$ | $\begin{aligned} & >89 \\ 78 & -89 \\ & <78 \end{aligned}$ | 0 22 0 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{4}$ No. = frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 7 | H | 8 | L | 9 | L | 10 | L | 11 | L | 12 | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} &>100 \\ & 87-100 \\ &<87 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >99 \\ 83 \end{array} \quad-99$ | $\begin{gathered} 1 \\ 23 \\ 23 \\ 0 \end{gathered}$ | $\begin{aligned} &>100 \\ & 92-100 \\ &<92 \\ & \hline \end{aligned}$ | $\begin{gathered} \hline 0 \\ 26 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 80 & -100 \\ & <80 \end{aligned}$ | $\begin{gathered} 1 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 97-100 \\ &<97 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 12 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 94-100 \\ &<94 \\ & \hline \end{aligned}$ | 1 <br> 53 <br> 1 |
| CD14+ | $\begin{aligned} &>1 \\ & 0-1 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 22 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 25 \\ \hline \end{gathered}$ | $\begin{aligned} &>4 \\ & 0-4 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 25 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 12 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | 1 <br> 53 <br> 0 |
| CD3+CD4+ | $\begin{aligned} &>39 \\ & 31-39 \\ &< \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 21 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >3 \\ 1 & -3 \\ & <1\end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >3 \\ 1 & -3 \\ & <1\end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >17 \\ 10 & -17 \\ & <10\end{aligned}$ | $\begin{gathered} 1 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >13 \\ 9 & -13 \\ & <9\end{aligned}$ | $\begin{gathered} 0 \\ 11 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>56 \\ & 48-56 \\ &<48 \\ & \hline \end{aligned}$ | 1 <br> 47 <br> 1 |
| CD3+CD8+ | $\begin{aligned} &>50 \\ & 39-50 \\ &<39 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 21 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>50 \\ & 30-50 \\ &<30 \\ & \hline \end{aligned}$ | $\begin{array}{\|c\|\|} \hline 1 \\ 20 \\ 0 \\ \hline \end{array}$ | $\begin{aligned} &>58 \\ & 49-58 \\ &<49 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} &>50 \\ & 33-50 \\ &<33 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>50 \\ & 40-50 \\ &<40\end{aligned}$ | $\begin{gathered} 0 \\ 11 \\ 0 \\ \hline \end{gathered}$ |  | 0 <br> 49 <br> 1 |
| CD3-CD19+ | $\begin{aligned} &>12 \\ & 5-12 \\ &<5 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>35 \\ & 24-35 \\ &<24 \\ & \hline \end{aligned}$ | $\begin{aligned} & 4 \\ & 9 \\ & 4 \\ & \hline \end{aligned}$ |  $>$ <br> 24  <br> 27 -34 <br> $<$  | $\begin{gathered} 0 \\ 15 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >11 \\ 6 & -11 \\ & <6\end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 17 \\ 0 \end{gathered}$ | $\begin{aligned} & >23 \\ 17 & -23 \\ & <17\end{aligned}$ | 0 <br> 9 <br> 1 | $\begin{aligned} & >13 \\ 7 & -13 \\ & <7\end{aligned}$ | 1 <br> 35 <br> 1 |
| CD3-(CD56 $\&$ CD16)+ | $\begin{array}{r} >9 \\ 3-9 \\ <3 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 16 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>23 \\ & 13-23 \\ &<13 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 13 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>14 \\ & 7-14 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>35 \\ & 24-35 \\ &<24 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 11 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>20 \\ & 11-20 \\ &<11\end{aligned}$ | 0 <br> 8 <br> 0 | $\begin{aligned} & >16 \\ 9 & -16 \\ & <9\end{aligned}$ | 1 <br> 25 <br> 3 |
| CD3+Average | $\begin{aligned} &>91 \\ & 77-91 \\ &< \\ & \hline \end{aligned}$ | $\begin{array}{r} 0 \\ 22 \\ 0 \\ \hline \hline \end{array}$ | $\begin{array}{r} >60 \\ 41 \end{array} \quad-60$ | $\begin{gathered} 1 \\ 17 \\ 3 \\ \hline \end{gathered}$ | $\begin{array}{r}  \\ >65 \\ 56-65 \\ \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 18 \\ 2 \\ 2 \\ \hline \hline \end{gathered}$ | $\begin{array}{r} >63 \\ 49-63 \\ < \end{array}$ | 0 25 0 | $\begin{aligned} &>64 \\ & 61-64 \\ &<61 \\ & \hline \end{aligned}$ | 0 <br> 9 <br> 2 |  | 1 <br> 47 <br> 2 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunod efic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\wedge}$ No. $=$ frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| opulation) | 13 | N | 14 - | N | 15 | N | 16 | H | 17 | H | 18 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 92 & -100 \\ & <92 \end{aligned}$ | $\begin{gathered} 0 \\ 53 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 96 & -100 \\ & <96 \end{aligned}$ | $\begin{gathered} 0 \\ 34 \\ 2 \end{gathered}$ | $\begin{aligned} & >99 \\ 91 & -99 \\ & <91 \end{aligned}$ | $\begin{gathered} 5 \\ 34 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 91 & -100 \\ & <91 \end{aligned}$ | $\begin{gathered} 0 \\ 26 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | $\begin{gathered} 0 \\ 32 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 1 \end{gathered}$ |
| CD14+ | $\begin{array}{r} >1 \\ 0 \end{array} \begin{array}{r} > \\ \\ < \end{array}$ | $\begin{gathered} 1 \\ 52 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0 \\ 0 \end{array} \quad 1$ | $\begin{gathered} 3 \\ 33 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 37 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ \\ < \end{array}$ | $\begin{gathered} 2 \\ 26 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \end{gathered}$ | $\begin{array}{r} >1 \\ 0 \\ 0 \end{array} \quad 1$ | 2 <br> 24 <br> 0 |
| CD3+CD4+ | $\begin{aligned} &>52 \\ & 47-52 \\ &<47 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 46 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>38 \\ & 33-38 \\ &<33 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 32 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>57 \\ & 49-57 \\ &<49 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 33 \\ 4 \\ \hline \end{gathered}$ | $\begin{array}{r} >32 \\ 24-32 \\ \\ <24 \end{array}$ | $\begin{gathered} 0 \\ 26 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >49 \\ 39 \end{array} \quad-49$ | $\begin{gathered} 2 \\ 20 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>30 \\ & 25-30 \\ &<25 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 21 \\ 1 \\ \hline \end{gathered}$ |
| CD3+CD8+ | $\begin{aligned} & >26 \\ 21 & -26 \\ & <21 \end{aligned}$ | $\begin{gathered} 2 \\ 46 \\ 2 \end{gathered}$ | $\begin{aligned} & >29 \\ 23 & -29 \\ & <23 \end{aligned}$ | $\begin{gathered} 1 \\ 32 \\ 3 \end{gathered}$ | $\begin{aligned} & >33 \\ 27 & -33 \\ & <27 \end{aligned}$ | $\begin{gathered} 1 \\ 34 \\ 2 \end{gathered}$ | $\begin{aligned} &>63 \\ & 54-63 \\ &<54 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 25 \\ 3 \end{gathered}$ | $\begin{aligned} & >31 \\ 26 & -31 \\ & <26 \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 1 \end{gathered}$ | $\begin{aligned} & >67 \\ 57 & -67 \\ & <57 \end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 2 \end{gathered}$ |
| CD3-CD19+ | $\begin{aligned} &>19 \\ & 12-19 \\ &<12 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 35 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >20 \\ 12 & -20 \\ & <12 \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 4-6 \\ <4 \end{array}$ | $\begin{gathered} 1 \\ 25 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >8 \\ 2-8 \\ \\ <2 \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >19 \\ 11 & -19 \\ & <11 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >3 \\ 1-3 \\ \\ \\ < \end{array}$ | $\begin{gathered} 2 \\ 22 \\ 0 \end{gathered}$ |
| CD3-(CD56 $\& C D 16)+$ | $\begin{array}{r} >9 \\ 6-9 \\ <6 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 29 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>17 \\ & 9-17 \\ &<9 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >10 \\ 2 & -10 \\ & <2 \end{aligned}$ | $\begin{gathered} 0 \\ 21 \\ 0 \end{gathered}$ | $\begin{aligned} & >15 \\ 9 & -15 \\ & <9 \end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 1 \end{gathered}$ | $\begin{array}{r} >8 \\ 4-8 \\ \\ <4 \end{array}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >4 \\ 2-4 \\ <2 \end{array}$ | 0 18 0 |
| CD3+Average | $\begin{aligned} & >78 \\ 73 & -78 \\ & <73 \end{aligned}$ | $\begin{gathered} 2 \\ 41 \\ 2 \end{gathered}$ | $\begin{aligned} & >75 \\ 66 & -75 \\ & <66 \end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 3 \end{gathered}$ | $\begin{aligned} & >89 \\ 81 & -89 \\ & <81 \end{aligned}$ | $\begin{gathered} 1 \\ 34 \\ 3 \end{gathered}$ | $\begin{aligned} & >87 \\ 79 & -87 \\ & <79 \end{aligned}$ | $\begin{gathered} 0 \\ 28 \\ 0 \end{gathered}$ | $\begin{aligned} & >80 \\ 67 & -80 \\ & <67 \end{aligned}$ | $\begin{gathered} 2 \\ 18 \\ 0 \end{gathered}$ | $\begin{array}{r} >96 \\ 85-96 \\ \\ <85 \end{array}$ | 0 21 1 |

*The $90 \%$ reference ranges were detemmined from results provided by participant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ No. = frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC DonorNumber -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 19-H |  | $20-\mathrm{H}$ |  | $21-\mathrm{H}$ |  | $22-\mathrm{H}$ |  | $23-\mathrm{M}$ |  | $24-L$ |  |
|  | Range | $\mathrm{No}^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 80 & -100 \\ & <80 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 0 \end{gathered}$ | $\begin{aligned} & >97 \\ 94 & -97 \\ & <94 \end{aligned}$ | $\begin{gathered} 13 \\ 6 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 96 & -100 \\ & <96 \end{aligned}$ | $\begin{gathered} 0 \\ 36 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 91 & -100 \\ & <91 \end{aligned}$ | 0 31 1 |
| CD14+ | $\begin{array}{r} >2 \\ 0-2 \\ \\ <0 \end{array}$ | $\begin{gathered} 0 \\ 28 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >20 \\ 0 & -20 \\ & <0 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ \\ <0 \end{array}$ | $\begin{gathered} 0 \\ 19 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ \\ < \end{array}$ | $\begin{gathered} 1 \\ 33 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 0 \end{gathered}$ | $\begin{array}{r} >7 \\ 0 \\ 0 \end{array} \begin{array}{r} > \\ \\ < \end{array}$ | 0 30 0 |
| CD3+CD4+ | $\begin{array}{r} >42 \\ 38-42 \\ \\ <38 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 25 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >43 \\ 35-43 \\ \\ <35 \\ \hline \end{array}$ | $\begin{gathered} 2 \\ 21 \\ 3 \\ \hline \end{gathered}$ | $\begin{array}{r} >36 \\ 33-36 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 14 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >25 \\ 18 & -25 \\ & <18 \end{aligned}$ | $\begin{gathered} 1 \\ 35 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>20 \\ & 16-20 \\ &<16 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 23 \\ 1 \end{gathered}$ | $\begin{aligned} & >12 \\ 8 & -12 \\ & <8 \end{aligned}$ | 1 <br> 23 <br> 1 |
| CD3+CD8+ | $\begin{array}{r} >48 \\ 39 \end{array} \begin{array}{r} >48 \\ \\ <39 \end{array}$ | $\begin{gathered} 1 \\ 25 \\ 0 \end{gathered}$ | $\begin{aligned} & >43 \\ 31 & -43 \\ & <31 \end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >44 \\ 41 & -44 \\ & <41 \end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 7 \\ & \hline \end{aligned}$ | $\begin{aligned} & >74 \\ 61 & -74 \\ & <61 \end{aligned}$ | $\begin{gathered} 1 \\ 34 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >51 \\ 39 & -51 \\ & <39 \end{aligned}$ | $\begin{gathered} 2 \\ 24 \\ 2 \end{gathered}$ | $\begin{aligned} & >73 \\ 63 & -73 \\ & <63 \end{aligned}$ | 0 <br> 24 <br> 1 |
| CD3-CD19+ | $\begin{aligned} & >10 \\ 6 & -10 \\ & <6 \end{aligned}$ | $\begin{gathered} 1 \\ 15 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >12 \\ 9 & -12 \\ & <9 \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>16 \\ & 13-16 \\ &<13 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 10 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >9 \\ 4-9 \\ \\ <4 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 27 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>13 \\ & 7-13 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 0 \end{gathered}$ | $\begin{aligned} &>10 \\ & 7-10 \\ &<7 \\ & \hline \end{aligned}$ | 0 <br> 21 <br> 2 |
| CD3-(CD56 $\& C D 16)+$ | $\begin{array}{r} >5 \\ 2-5 \\ \\ <2 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 17 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 2-6 \\ \\ <2 \\ \hline \end{array}$ | $\begin{gathered} 2 \\ 12 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 3-6 \\ < \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >3 \\ 1-3 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>21 \\ & 16-21 \\ &<16 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >9 \\ 2-9 \\ \\ <2 \\ \hline \end{array}$ | 0 14 0 |
| CD3+Average | $\begin{aligned} & >87 \\ 79 & -87 \\ & <79 \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 1 \end{gathered}$ | $\begin{aligned} & >88 \\ 79 & -88 \\ & <79 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \end{gathered}$ | $\begin{aligned} & >82 \\ 80 & -82 \\ & <80 \end{aligned}$ | $\begin{aligned} & 2 \\ & 7 \\ & 8 \end{aligned}$ | $\begin{aligned} & >95 \\ 88 & -95 \\ & <88 \end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 1 \end{gathered}$ | $\begin{aligned} & >73 \\ 61 & -73 \\ & <61 \end{aligned}$ | $\begin{gathered} 1 \\ 25 \\ 0 \end{gathered}$ | $\begin{aligned} & >92 \\ 81 & -92 \\ & <81 \end{aligned}$ | 0 21 2 |

*The $90 \%$ reference ranges were detemmined from results provided by participant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ No. = frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker (Population) | V |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25 | L | 26 | M | 27 | N | 28 | N | 29 | N | 30 | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No |
| CD45+ | $\begin{aligned} &>100 \\ & 77-100 \\ &<77 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 0 \end{gathered}$ | $\begin{aligned} &>100 \\ & 92-100 \\ &<92 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 94-100 \\ &<94 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 48 \\ 2 \end{gathered}$ | $\begin{aligned} &>100 \\ & 96-100 \\ &<96 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 55 \\ 5 \\ 4 \end{gathered}$ | $\begin{aligned} &>100 \\ & 95-100 \\ &<95 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 48 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | 0 39 1 |
| CD14+ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0 \end{aligned}$ | $\begin{gathered} 1 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 4 \\ 47 \\ 0 \end{gathered}$ | $\begin{aligned} &> \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 57 \\ 57 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >3 \\ 0-3 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 46 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ 0 \end{array}$ | 1 38 0 |
| CD3+CD4+ | $\begin{aligned} &>16 \\ & 14-16 \\ &<14 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $18-22$ $<18$ | $\begin{gathered} 0 \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>48 \\ & 35-48 \\ &<35 \\ & \hline \end{aligned}$ | $\begin{array}{\|c\|} \hline 3 \\ 42 \\ 1 \\ \hline \end{array}$ | $\begin{aligned} &>53 \\ & 42-53 \\ &<42 \\ & \hline \end{aligned}$ | $\begin{array}{\|c\|\|} \hline 1 \\ 47 \\ 3 \\ \hline \end{array}$ | $\begin{aligned} &>46 \\ & 41-46 \\ &<41 \\ & \hline \end{aligned}$ | $\begin{gathered} 3 \\ 35 \\ 3 \\ 5 \\ \hline \end{gathered}$ | $\begin{aligned} &>69 \\ & 63-69 \\ &<63 \\ & \hline \end{aligned}$ | 0 37 0 |
| CD3+CD8+ | $\begin{aligned} &>64 \\ & 49-64 \\ &<49 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $45-52$ $<45$ | $\begin{array}{\|c\|\|} \hline 1 \\ 17 \\ 0 \\ 0 \end{array}$ | $\begin{aligned} &>27 \\ & 19-27 \\ &<19 \\ & \hline \end{aligned}$ | $\begin{gathered} 3 \\ 43 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>24 \\ & 16-24 \\ &<16 \\ & \hline \end{aligned}$ | $\begin{array}{\|c\|\|} \hline 4 \\ 46 \\ 3 \\ \hline \end{array}$ | $\begin{aligned} &>22 \\ & 15-22 \\ &<15 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 39 \\ 2 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>21 \\ & 18-21 \\ &<18 \\ & \hline \end{aligned}$ | $\begin{array}{r}1 \\ 33 \\ 3 \\ \hline\end{array}$ |
| CD3-CD19+ | $\begin{aligned} & >11 \\ 7 & -11 \\ & <7 \end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>19 \\ & 12-19 \\ &<12 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 0 \\ 13 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >23 \\ 16 & -23 \\ & <16 \end{aligned}$ | $\begin{gathered} 2 \\ 29 \\ 4 \\ \hline \end{gathered}$ | $\begin{aligned} & >16 \\ 11 & -16 \\ & <11 \end{aligned}$ | $\begin{gathered} 2 \\ 38 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >18 \\ 13 & -18 \\ & <13 \end{aligned}$ | $\begin{gathered} 0 \\ 37 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >9 \\ 6-9 \\ <6 \\ \hline \end{array}$ | 1 30 0 |
| CD3-(CD56 $\&$ CD16)+ | $\begin{aligned} &>12 \\ & 7-12 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >11 \\ 8 & -11 \\ & <8 \end{aligned}$ | $\begin{array}{l\|\|} 0 \\ 9 \\ 1 \\ 1 \end{array}$ | $\begin{aligned} & >13 \\ 9 & -13 \\ & <9 \end{aligned}$ | $\begin{gathered} 0 \\ 29 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >14 \\ 10 & -14 \\ & <10 \end{aligned}$ | $\begin{gathered} 2 \\ 27 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} & 12-16 \\ &<12 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >8 \\ 4-8 \\ \\ <4 \\ \hline \end{array}$ | 0 23 0 |
| CD3+Average | $\begin{array}{r} >89 \\ 75-89 \\ <\quad 75 \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >76 \\ 69 & -76 \\ & <69 \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 14 \\ 1 \end{gathered}$ | $\begin{array}{r} >72 \\ 63-72 \\ \\ <63 \end{array}$ | $\begin{gathered} 3 \\ 41 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >76 \\ 68-76 \\ \\ <68 \end{array}$ | $\begin{gathered} 2 \\ 45 \\ 2 \\ 2 \end{gathered}$ | $\begin{aligned} &>71 \\ & 65-71 \\ &<65 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 37 \\ 1 \end{gathered}$ | $\begin{aligned} & >89 \\ 84 & -89 \\ & <84 \end{aligned}$ | 1 31 2 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct (<200), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ No. $=$ frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC DonorNumber -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $31-\mathrm{H}$ |  | $32-\mathrm{H}$ |  | $33-\mathrm{H}$ |  | $34-\mathrm{H}$ |  | $35-\mathrm{H}$ |  | $36-\mathrm{H}$ |  |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 26 \\ 4 \\ \hline \end{gathered}$ | $\begin{aligned} & >99 \\ 86 & -99 \\ & <86 \end{aligned}$ | $\begin{gathered} 0 \\ 29 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | $\begin{gathered} 0 \\ 33 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | $\begin{gathered} 0 \\ 33 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | 0 <br> 26 <br> 2 |
| CD14+ | $\begin{array}{r} >2 \\ 0-2 \\ \\ < \end{array}$ | $\begin{array}{c\|} 1 \\ 29 \\ 0 \\ \hline \end{array}$ | $\begin{array}{r} >4 \\ 0-4 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0 \end{aligned}$ | $\begin{gathered} 0 \\ 33 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ < \end{array}$ | $\begin{gathered} 0 \\ 32 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ 0 \end{array}$ | $\begin{gathered} 1 \\ 33 \\ 0 \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0 \end{aligned}$ | 2 <br> 24 <br> 0 |
| CD3+CD4+ | $\begin{array}{r} >24 \\ 19-24 \\ \\ <19 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r}  \\ >39 \\ 31 \end{array} \quad 39$ | $\begin{gathered} 1 \\ 30 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>30 \\ & 23-30 \\ &<23 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 28 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >41 \\ 32 & -41 \\ & <32 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>50 \\ & 40-50 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 28 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >22 \\ 18-22 \\ \\ <18 \\ \hline \end{array}$ | 3 25 0 |
| CD3+CD8+ | $\begin{aligned} &>63 \\ & 51-63 \\ &<51 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >47 \\ 39 & -47 \\ & <39 \end{aligned}$ | $\begin{gathered} 0 \\ 31 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>63 \\ & 52-63 \\ &<52 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 4 \\ \hline \end{gathered}$ | $\begin{array}{r} >46 \\ 33-46 \\ \\ <33 \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>33 \\ & 23-33 \\ &<23 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 29 \\ 0 \end{gathered}$ | $\begin{aligned} &>74 \\ & 67-74 \\ &<67 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 3 \\ \hline \end{gathered}$ |
| CD3-CD19+ | $\begin{array}{r} >9 \\ 6-9 \\ <6 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>17 \\ & 11-17 \\ &<11 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >10 \\ 5 & -10 \\ & <5 \end{aligned}$ | $\begin{gathered} 0 \\ 27 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >16 \\ 8 & -16 \\ & <8 \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \end{gathered}$ | $\begin{aligned} &>14 \\ & 10-14 \\ &<10 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 3-6 \\ \\ <3 \end{array}$ | 0 <br> 20 <br> 0 |
| CD3-(CD56 $\& C D 16)+$ | $\begin{array}{r} >4 \\ 1-4 \\ \\ \\ < \end{array}$ | $\begin{aligned} & 0 \\ & 9 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{array}{r} >6 \\ 4-6 \\ <4 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 12 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 1-6 \\ \\ \\ < \end{array}$ | $\begin{gathered} 1 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >9 \\ 2-9 \\ \\ <2 \end{array}$ | $\begin{gathered} 0 \\ 12 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >9 \\ 7-9 \\ \end{array} \begin{array}{r} >7 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >7 \\ 5-7 \\ \\ <5 \\ \hline \end{array}$ | 0 <br> 14 <br> 0 |
| CD3+Average | $\begin{aligned} & >89 \\ 79 & -89 \\ & <79 \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \end{gathered}$ | $\begin{aligned} & >83 \\ 72 & -83 \\ & <72 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ | $\begin{aligned} & >90 \\ 84 & -90 \\ & <84 \end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 2 \end{gathered}$ | $\begin{aligned} & >81 \\ 69 & -81 \\ & <69 \end{aligned}$ | $\begin{gathered} 2 \\ 26 \\ 0 \end{gathered}$ | $\begin{aligned} & >81 \\ 72 & -81 \\ & <72 \end{aligned}$ | $\begin{gathered} 3 \\ 30 \\ 1 \end{gathered}$ | $\begin{aligned} & >90 \\ 87 & -90 \\ & <87 \end{aligned}$ | 0 21 3 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\Delta}$ No. $=$ frequency of laboratories

Table 1. Frequency of 2-c olor laboratory results for the September 1995 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC DonorNumber -

| Cell Marker HIV Status** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| , | 38 |  | 39 | L | 40 | L | 42 | N | 43 | N | 44 | N | 45 | N |
|  | Range No | No. ${ }^{\text {. }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\left\lvert\, \begin{array}{\|cc\|}  & >100 \\ 92 & -100 \\ & <92 \end{array}\right.$ | $\begin{gathered} 0 \\ 27 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 80 & -100 \\ & <80 \end{aligned}$ | 0 32 0 | $\begin{aligned} & >100 \\ 90 & -100 \\ & <90 \end{aligned}$ | $\begin{gathered} 0 \\ 29 \\ 1 \end{gathered}$ | $\left\lvert\, \begin{aligned} &>100 \\ & 94-100 \\ &<94 \\ & \hline \end{aligned}\right.$ | $\begin{gathered} 0 \\ 58 \\ 4 \\ \hline \end{gathered}$ | $\begin{array}{\|rl}  & >100 \\ 93 & -100 \\ & <93 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 58 \\ 5 \\ \hline \end{gathered}$ | $\left\lvert\, \begin{array}{\|cc\|}  & >100 \\ 88 & -100 \\ <88 \end{array}\right.$ | $\begin{gathered} 0 \\ 30 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 92 & -100 \\ & <92 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 1 \\ \hline \end{gathered}$ |
| CD14+ | $\begin{array}{r} >2 \\ 0-2 \\ <0 \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline 0 \\ 30 \\ 0 \\ \hline \end{array}$ | $\begin{array}{r} >5 \\ 0-5 \\ <0 \end{array}$ | $\begin{gathered} 0 \\ 32 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 28 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >3 \\ 0-3 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 2 \\ 59 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 62 \\ 0 \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 29 \\ 0 \end{gathered}$ |
| CD3+CD4+ | $\begin{array}{r} >2 \\ 0-2 \\ 0 \end{array}$ | $\begin{array}{\|c\|} \hline 0 \\ 27 \\ 0 \\ \hline \end{array}$ | $\begin{array}{r} >2 \\ 0-2 \\ 0 \end{array}$ | $\begin{gathered} 1 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >8 \\ 5-8 \\ <5 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 28 \\ 1 \\ \hline \end{gathered}$ | $\left\lvert\, \begin{aligned} &> 29 \\ & 17-29 \\ &< 17 \\ & \hline \end{aligned}\right.$ | $\begin{gathered} 2 \\ 52 \\ 4 \\ \hline \end{gathered}$ | $\begin{array}{r} >47 \\ 39-47 \\ <39 \end{array}$ | $\begin{gathered} 1 \\ 56 \\ 1 \\ \hline \end{gathered}$ | 46-52 <br> $<46$ | $\begin{gathered} 1 \\ 28 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >66 \\ 55-66 \\ <55 \end{array}$ | $\begin{gathered} 2 \\ 27 \\ 0 \\ \hline \end{gathered}$ |
| CD3+CD8+ | $\begin{array}{rr}  & >48 \\ 36 & -48 \\ <36 \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline 0 \\ 24 \\ 3 \\ \hline \end{array}$ | $\begin{array}{r} >60 \\ 54-60 \\ <54 \end{array}$ | $\begin{gathered} 1 \\ 28 \\ 2 \end{gathered}$ | $\begin{aligned} &>81 \\ & 69-81 \\ &<69 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 27 \\ 3 \\ \hline \end{gathered}$ | $\begin{array}{r} >53 \\ 35-53 \\ <35 \end{array}$ | $\begin{gathered} 4 \\ 49 \\ 5 \end{gathered}$ | $\begin{array}{r} \quad>28 \\ 22-28 \\ <22 \end{array}$ | $\begin{gathered} 1 \\ 54 \\ 3 \end{gathered}$ | $\begin{aligned} & >11 \\ 8 & -11 \\ & <8 \end{aligned}$ | $\begin{gathered} 2 \\ 28 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >27 \\ 17-27 \\ <17 \end{array}$ | $\begin{gathered} 0 \\ 29 \\ 0 \\ \hline \end{gathered}$ |
| CD3-CD19+ | $\begin{array}{r} >25 \\ 15-25 \\ <15 \\ \hline \end{array}$ | $\begin{array}{\|c\|} \hline 2 \\ 16 \\ 2 \\ \hline \end{array}$ | $\begin{array}{r} >30 \\ 16 \\ -30 \\ <16 \end{array}$ | $\begin{gathered} 0 \\ 24 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>12 \\ & 5-12 \\ &<5 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 22 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>12 \\ & 5-12 \\ &<5 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 43 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{\|r}  \\ 13 \\ 19 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 44 \\ 1 \\ \hline \end{gathered}$ | $\left\lvert\, \begin{array}{r} >30 \\ 22 \end{array} \quad-30\right.$ | $\begin{gathered} 2 \\ 21 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >13 \\ 7-13 \\ <7 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 23 \\ 0 \\ \hline \end{gathered}$ |
| $\begin{aligned} & \text { CD3-(CD56 } \\ & \& \text { CD16)+ } \end{aligned}$ | $\begin{array}{\|rr}  & >21 \\ 13 & -21 \\ <13 \\ \hline \end{array}$ | $\begin{array}{\|l\|} \hline 4 \\ 4 \\ 3 \\ \hline \end{array}$ | $\begin{aligned} &>12 \\ & 8-12 \\ &<8 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >7 \\ 1-7 \\ <1 \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>20 \\ & 9-20 \\ &<9 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 5 \\ \hline \end{gathered}$ | $\begin{aligned} &>11 \\ & 8-11 \\ &<8 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>14 \\ & 8-14 \\ &<8 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >6 \\ 3-6 \\ <3 \end{array}$ | 0 <br> 14 <br> 0 |
| CD3+ <br> Average | $\left\lvert\, \begin{aligned} & >60 \\ 46 & -60 \\ & <46 \end{aligned}\right.$ | $\begin{gathered} 1 \\ 23 \\ 2 \\ 2 \end{gathered}$ | $\begin{array}{r} >65 \\ 54-65 \\ \\ <54 \end{array}$ | 3 26 0 | 80-91 <br> $<80$ | 0 27 0 | $\left\lvert\, \begin{aligned} &>80 \\ & 69-80 \\ &<69 \end{aligned}\right.$ | 3 47 4 | $\begin{array}{r}  \\ \hline 67 \\ 66 \\ \hline \end{array}$ | 4 <br> 48 <br> 3 | $\begin{aligned} &>64 \\ & 55-64 \\ &<55 \end{aligned}$ | 0 <br> 25 <br> 1 | $\begin{array}{r} >86 \\ 75-86 \\ <75 \end{array}$ | 3 <br> 26 <br> 0 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-C ell Determinations in Persons with Human Immunodefic iency Virus (HV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\wedge}$ No. = frequency of laboratories

Table 2. Range of all partic ipant laboratory results for the March 1994 shipment for CD16 and CD56 cell markers. Insuffic ient data were reported by laboratories using the recommended monoclonal antibody panel to enable determination of $90 \%$ reference ranges. The ranges reported in this table are the maximum and minimum values

| Donor Number | $\begin{aligned} & \hline \hline \text { HIV } \\ & \text { Status } \end{aligned}$ | $\begin{gathered} \hline \hline \text { CD3-/CD16+ } \\ \text { Range } \\ \hline \end{gathered}$ |  |  | $\begin{gathered} \hline \hline \text { CD3-/CD56+ } \\ \text { Range } \end{gathered}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 01 | H | 0 |  | 0 | 6 | - | 11 |
| 02 | H |  | NA |  | 4 | - | 4 |
| 03 | H | 2 | - | 3 | 0 | - | 1 |
| 04 | H | 1 | - | 2 | 3 | - | 5 |
| 05 | H | 7 | - | 9 | 2 | - | 6 |
| 06 | H | 8 | - | 12 | 4 | - | 6 |
| 07 | L | 0 | - | 5 | 8 | - | 11 |
| 08 | M | 5 | - | 5 | 2 | - | 6 |
| 09 | L | 10 | - | 12 | 3 | - | 8 |
| 10 | N | 2 | - | 8 | 4 | - | 11 |
| 11 | N | 6 | - | 9 | 5 | - | 9 |
| 12 | N | 9 | - | 11 | 7 | - | 26 |
| 13 | H |  | NA |  | 1 | - | 4 |
| 14 | H | 4 | - | 5 | 4 | - | 4 |
| 15 | H | 3 | - | 10 | 1 | - | 9 |
| 16 | H |  | NA |  | 4 | - | 7 |
| 17 | H | 0 |  | 7 | 2 | - | 7 |
| 18 | H | 2 | - | 3 | 1 | - | 1 |
| 19 | L |  | NA |  | 3 | - | 16 |
| 20 | L | 1 | - | 6 | 2 | - | 15 |
| 21 | M | 1 | - | 4 | 1 | - | 3 |
| 22 | N | 4 | - | 7 | 2 | - | 18 |
| 23 | N | 4 | - | 11 | 4 | - | 12 |
| 24 | N | 3 | - | 18 | 2 | - | 20 |
| 25 | H |  | NA |  |  | NA |  |
| 26 | H | 7 | - | 9 | 5 | - | 10 |
| 27 | H |  | NA |  | 19 | - | 20 |
| 28 | H | 4 | - | 8 | 2 | - | 8 |
| 29 | H |  | NA |  | 1 | - | 4 |
| 30 | H |  | NA |  | 8 | - | 14 |
| 31 | L | 2 |  | 10 | 1 | - | 7 |
| 32 | M | 4 | - | 4 | 1 | - | 6 |
| 33 | M |  | NA |  | 7 | - | 14 |
| 34 | N | 5 |  | 10 | 2 | - | 10 |
| 35 | N | 5 |  | 6 | 2 | - | 9 |
| 36 | N | 20 | - | 21 | 15 | - | 25 |

Table 3. Percentage of 2-color la boratory results for the September 1995 shipment, by monoclonal antibody ma nufacturer, that are within the $90 \%$ reference ranges*

| n ( $\mathrm{N}=125)^{* *}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker (Population) | CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 88 | 83 | 93 | 93 | 75 | 100 | 100 | 91 | 100 | 92 | 100 | 93 | 92 | 89 | 88 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 92 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 94 | 100 | 100 | 100 |
| CD3+CD4+ | 93 | 100 | 100 | 93 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 96 | 89 | 100 | 100 | 63 | 94 |
| CD3+CD8+ | 93 | 75 | 86 | 93 | 88 | 83 | 100 | 100 | 80 | 100 | 100 | 96 | 88 | 84 | 88 | 100 | 88 | 94 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 100 | 100 | 83 | 96 | 100 | 86 | 88 | 100 | 100 | 10 |
| CD3-(CD56 \& CD16)+ |  | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 100 | 82 | 100 | 83 | 100 | 94 | 100 | 100 | 100 | 10 |
| CD3+Average | 93 | 100 | 100 | 100 | 88 | 100 | 100 | 100 | 100 | 100 | 100 | 96 | 91 | 88 | 94 | 100 |  | 10 |

Coulter $(\mathrm{N}=66)^{* *}$

| Cell Marker | CDC | D | Nu | er |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 4 | 15 | 16 | 7 | 18 |
| HIV Status** | H | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 100 | 100 | 90 | 100 | 83 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 85 | 100 | 100 | 100 |
| CD14+ | 67 | 100 | 100 | 100 | 100 | 67 | 100 | 83 | 100 | 88 | 100 | 93 | 92 | 75 | 100 | 100 | NA | 100 |
| CD3+CD4+ | 100 | 75 | 80 | 88 | 70 | 100 | 83 | 100 | 100 | 88 | 100 | 93 | 93 | 88 | 77 | 100 | 50 | 50 |
| CD3+CD8+ | 75 | 100 | 90 | 100 | 90 | 67 | 83 | 86 | 71 | 100 | 100 | 100 | 93 | 88 | 92 | 75 | 100 | 50 |
| CD3-CD19+ | 100 | NA | 100 | 100 | 100 | NA | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | NA |
| CD3-(CD56 \& CD16)+ | +NA | NA | NA | 100 | NA | NA | NA | 100 | NA | NA | NA | 100 | 100 | NA | NA | NA | NA | NA |
| CD3+Average | 88 | NA | 90 | 100 | 100 | 100 | 100 | 67 | 80 | 100 | 100 | 93 | 92 | 60 | 82 | 100 | 0 |  |


| Cell Marker | CD | Dono | r Nu |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 83 | 100 | 100 | 100 | 90 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 | 80 | 92 | 88 |
| CD14+ | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 90 | 90 | 80 | 100 | 75 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 86 | 91 | 89 | 86 | 100 | 100 | 83 |
| CD3+CD8+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 70 | 100 | 83 |
| CD3-CD19+ | 100 | 100 | NA | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 83 | 100 | 100 | 100 | 100 | 100 | 75 |
| CD3-(CD56 \& CD16)+ | +NA | 100 | NA | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | 100 | 100 | 83 | 100 | 100 |
| CD3+Average | 100 | 100 | 700 | 100 | 63 | 100 | 100 | 50 | 86 | 100 | 67 | 89 | 91 | 100 | 89 | 100 | 100 | 83 |

[^1]Table 3. Percentage of 2-color la boratory results for the September 1995 shipment, by monoclonal antibody ma nufacturer, that are within the $90 \%$ reference ranges*

| Becton-Dickinson ( $\mathrm{N}=125)^{* *}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status*** | H | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 94 | 100 | 100 | 100 | 93 | 100 | 100 | 100 | 96 | 83 | 94 | 95 | 90 | 90 | 100 | 100 | 92 |  |
| CD14+ | 100 | 100 | 100 | 94 | 100 | 100 | 100 | 100 | 96 | 100 | 94 | 100 | 90 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 94 | 70 | 100 | 94 | 93 | 78 | 100 | 100 | 88 | 96 | 88 | 100 | 100 | 80 | 94 | 100 | 92 | 86 |
| CD3+CD8+ | 94 | 90 | 100 | 94 | 93 | 89 | 100 | 88 | 92 | 83 | 82 | 95 | 90 | 100 | 94 | 100 | 92 | 86 |
| CD3-CD19+ | 93 | 75 | 100 | 100 | 100 | 100 | 100 | 100 | 82 | 88 | 100 | 94 | 100 | 100 | 100 | 100 | 90 |  |
| CD3-(CD56 \& CD16)+ | 93 | 100 | 100 | 100 | 92 | 100 | 100 | 100 | 100 | 94 | 100 | 100 | 75 | 100 | 93 | 100 | 100 | 100 |
| CD3+Average | 94 | 75 | 100 | 93 | 93 | 86 | 100 | 86 | 83 | 90 | 100 | 88 | 90 | 100 | 94 | 100 | 100 | 83 |

## Coulter ( $\mathrm{N}=66)^{* *}$

| Cell Marker C | CDC | Dono | Num | er |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status*** | H | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 92 | 75 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 100 | 100 | 86 | 83 | 100 | 100 | 100 | 60 | 100 | 100 | 90 |
| CD3+CD8+ | 100 | 100 | 0 | 100 | 60 | 100 | 100 | 100 | 89 | 88 | 100 | 83 | 100 | 93 | 60 | 100 | 100 | 90 |
| CD3-CD19+ | NA | 100 | NA | 100 | 100 | 100 | NA | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 90 | 10 |
| CD3-(CD56 \& CD16)+ |  | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| CD3+Average | 700 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 86 | 100 | 100 | 100 | 100 | 0 | 83 | 83 | 88 |

## Other Manufacturers $(\mathrm{N}=100)^{* * * *}$

| CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status** | H | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 100 | 100 | 0 | 100 | 89 | 95 | 100 | 100 | 88 | 97 | 96 | 100 | 81 | 100 | 100 | 86 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 100 | 89 | 100 | 88 | 100 | 88 | 97 | 100 | 93 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | 83 | 75 | 100 | 88 | 100 | 80 | 100 | 92 | 90 | 75 | 100 | 100 | 100 | 100 | 100 | 83 | 100 |
| CD3+CD8+ | 100 | 100 | 50 | 93 | 88 | 100 | 100 | 100 | 85 | 90 | 95 | 83 | 100 | 100 | 80 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 88 | 100 | 87 | 100 | 100 | 80 | 95 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | +100 | 75 | 100 | 88 | 100 | 100 | 100 | 75 | 71 | 71 | 92 | 100 | 100 | 50 | 100 | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 13 | 91 | 100 | 92 | 100 | 100 | 93 | 95 | 95 | 92 | 100 | 100 | 92 | 93 | 88 | 100 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
**La boratories using Becton Dic kinson or Coulter monoc lonal antibodies exc lusively for all tests.
*** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$
****Results from laboratories using monoclonal a ntibodies from more than one manufacturer or from Dako, Caltag, GeI Immunotech, In-house, Ortho, Pharmingen, or Sigma.
NA = no data retumed by any laboratory for specified marker

# Table 3. Percentage of 2-color laboratory results for the September 1995 shipment, by monoclonal a ntibody ma nufacturer, that are within the $90 \%$ reference ranges* 

Becton-Dickinson ( $\mathrm{N}=125$ )**

| Cell Marker | CDC Donor Number |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 38 | 39 | 40 | 42 | 43 | 44 | 45 |
| HIV Status*** | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 92 | 90 | 92 | 100 |
| CD14+ | 100 | 100 | 100 | 96 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 85 | 100 |
| CD3+CD8+ | 100 | 100 | 100 | 88 | 90 | 92 | 100 |
| CD3-CD19+ | 67 | 100 | 93 | 95 | 94 | 85 | 100 |
| CD3-(CD56 \& CD16)- | 20 | 100 | 100 | 89 | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | 83 | 95 | 92 | 100 |


| Cell Marker (Population) | coulter ( $\mathrm{N}=66$ )** |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Donor Number |  |  |  |  |  |  |
|  | 38 | 39 | 40 | 42 | 43 | 44 | 45 |
| HIV Status*** | L | L | L | N | N | N | N |
| CD45+ | 83 | 100 | 88 | 93 | 94 | 100 | 91 |
| CD14+ | 100 | 100 | 86 | 92 | 100 | 100 | 90 |
| CD3+CD4+ | 100 | 100 | 75 | 79 | 89 | 89 | 82 |
| CD3+CD8+ | 67 | 85 | 75 | 79 | 95 | 78 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)- | NA | NA | NA | NA | NA | NA | NA |
| CD3+Average | 80 | 82 | 100 | 80 | 75 | 100 | 70 |


| Other Ma nufa c turers ( $\mathrm{N}=100$ |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC (Population) HIV Status*** | Don | Num | ber |  |  |  |  |
|  | 38 | 39 | 40 | 42 | 43 | 44 | 45 |
|  | L | L | L | N | N | N | N |
| CD45+ | 86 | 100 | 100 | 96 | 92 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 100 | 96 | 90 | 100 |
| CD3+CD4+ | 100 | 86 | 100 | 83 | 100 | 100 | 100 |
| CD3+CD8+ | 91 | 86 | 86 | 83 | 94 | 100 | 100 |
| CD3-CD19+ | 82 | 80 | 86 | 94 | 100 | 71 | 100 |
| CD3-(CD56 \& CD16)- | 50 | 75 | 100 | 71 | 90 | 88 | 100 |
| CD3+Average | 83 | 86 | 100 | 95 | 95 | 100 | 100 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc v Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
**La bora tories using Becton Dic kinson or Coulter monoc lonal a ntibodies exc lusively for all tests.
*** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ***Results from laboratories using monoclonal a ntibodies from more than one manufacturer or from Dako, Caltag, Gel Immunotech, In-house, Ortho, Pharmingen, or Sigma.
$N A=$ no data retumed by any laboratory for specified marker

Table 4. Percentage of 2-color laboratory results for the September 1995 shipment, by equipment manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=121$ )

| Cell Marker | CDC | Dono | Num |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 80 | 88 | 90 | 70 | 100 | 100 | 100 | 100 | 89 | 100 | 95 | 95 | 94 | 100 | 100 | 86 | 100 |
| CD14+ | 100 | 100 | 100 | 89 | 80 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 87 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 90 | 80 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 95 | 88 | 93 | 100 | 70 | 100 |
| CD3+CD8+ | 100 | 90 | 75 | 90 | 90 | 100 | 100 | 100 | 90 | 100 | 100 | 100 | 90 | 88 | 93 | 100 | 90 | 93 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 83 | 100 | 100 | 86 | 85 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16) + | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 94 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | 100 | 88 | 100 | 100 | 88 | 100 | 100 | 100 | 100 | 89 | 88 | 93 | 100 | 100 | 100 |


| Coulter ( $\mathrm{N}=151$ ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 79 | 100 | 100 | 100 | 94 | 100 | 92 | 93 | 100 | 100 | 100 | 97 | 97 | 94 | 74 | 89 | 100 | 90 |
| CD14+ | 83 | 100 | 100 | 100 | 100 | 83 | 100 | 92 | 100 | 93 | 100 | 97 | 96 | 83 | 100 | 89 | 100 | 80 |
| CD3+CD4+ | 90 | 92 | 100 | 93 | 79 | 100 | 90 | 100 | 100 | 93 | 100 | 100 | 96 | 94 | 90 | 100 | 90 | 63 |
| CD3+CD8+ | 75 | 83 | 100 | 100 | 93 | 67 | 90 | 91 | 77 | 100 | 100 | 96 | 92 | 88 | 95 | 85 | 100 | 75 |
| CD3-CD19+ 1 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 43 | 100 | 100 | 100 | 94 | 100 | 100 | 100 | 100 | 100 | 75 |
| CD3-(CD56 \& CD16)+ 1 | 100 | 100 | 100 | 100 | 67 | 0 | 100 | 100 | 100 | 50 | 100 | 80 | 92 | 86 | 100 | 92 | 100 | 100 |
| CD3+Average | 83 | 100 | 100 | 100 | 94 | 100 | 100 | 73 | 80 | 100 | 75 | 96 | 96 | 83 | 90 | 100 | 75 | 88 |

Ortho ( $\mathrm{N}=19$ )
Cell Marker CDC Donor Number

| (Population) |  | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HIV Status** |  | H | H | H | H | H | H | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 100 | NA | 100 | 00 | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 10 |
| CD14+ | 100 | 100 | 100 | NA | 100 | 100 | NA | 10 | 100 | 100 | NA | 10 | 100 | 100 | 100 | 100 | 00 | 100 |
| CD3+CD4+ | 100 | 100 | 0 | NA | 0 | 100 | NA | 100 | 100 | 100 | NA | 50 | 75 | 50 | 50 | 100 | 100 | 100 |
| CD3+CD8+ | 100 | 100 | 50 | NA | 100 | 100 | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 50 | 50 | 100 | 100 |
| CD3-CD19+ 100 | 100 | 100 | NA | NA | 100 | 100 | NA | 0 | 100 | 100 | NA | 67 | 100 | 100 | 100 | NA | 100 | 100 |
| CD3-(CD56 \& CD16)+ | 100 | NA | NA | NA | NA | 100 | NA | 100 | NA | 100 | NA | 50 | 100 | 100 | NA | NA | 100 | NA |
| CD3+Average | 100 | 700 | 50 | NA | 0 | 100 | NA | 100 | 100 | 100 | NA | 50 | 75 | 100 | 50 | 100 | 100 | 100 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^2]Table 4. Percentage of 2-color laboratory results for the September 1995 shipment, by equipment manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=121$ )

| Cell Marker | CDC | Dono | N Num |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status** | H | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 94 | 100 | 60 | 100 | 92 | 92 | 100 | 100 | 96 | 84 | 90 | 95 | 100 | 93 | 100 | 86 | 90 | 100 |
| CD14+ | 100 | 100 | 100 | 94 | 100 | 100 | 100 | 100 | 96 | 100 | 95 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 94 | 75 | 88 | 94 | 92 | 91 | 91 | 100 | 87 | 91 | 74 | 100 | 100 | 86 | 93 | 100 | 90 | 89 |
| CD3+CD8+ | 94 | 92 | 100 | 94 | 92 | 91 | 100 | 88 | 91 | 83 | 79 | 95 | 83 | 100 | 93 | 100 | 90 | 89 |
| CD3-CD19+ | 93 | 80 | 100 | 93 | 100 | 89 | 100 | 100 | 80 | 89 | 100 | 94 | 100 | 100 | 100 | 100 | 88 | 100 |
| CD3-(CD56 \& CD16)+ | 93 | 75 | 100 | 100 | 90 | 100 | 100 | 100 | 100 | 88 | 92 | 100 | 100 | 100 | 92 | 100 | 100 | 100 |
| CD3+Average | 94 | 80 | 70 | 86 | 91 | 89 | 100 | 86 | 82 | 90 | 94 | 89 | 100 | 100 | 100 | 100 | 100 | 88 |


| Coulter ( $\mathrm{N}=151$ ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker (Population) |  | Dono | r Num |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status** | * | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 100 | 100 | 0 | 100 | 93 | 100 | 100 | 100 | 92 | 97 | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 80 |
| CD14+ | 100 | 100 | 100 | 100 | 93 | 100 | 90 | 100 | 88 | 97 | 100 | 94 | 95 | 100 | 100 | 100 | 95 | 75 |
| CD3+CD4+ | 100 | 83 | 100 | 100 | 83 | 91 | 100 | 100 | 95 | 91 | 95 | 100 | 100 | 100 | 85 | 100 | 100 | 90 |
| CD3+CD8+ | 100 | 100 | 0 | 95 | 79 | 100 | 100 | 100 | 86 | 88 | 100 | 82 | 100 | 94 | 85 | 100 | 100 | 90 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 91 | 100 | 86 | 86 | 95 | 100 | 100 | 100 | 100 | 100 | 100 | 94 | 100 |
| CD3-(CD56 \& C CD3+Average | 100 | 100 | 100 | 90 | 100 | 100 | 100 | 80 | 82 | 75 | 100 | 100 | 83 | 50 | 100 | 100 | 100 | NA |
|  | 100 | 700 | 0 | 100 | 100 | 91 | 100 | 100 | 95 | 92 | 100 | 93 | 94 | 100 | 82 | 86 | 85 | 88 |
|  |  |  |  |  |  |  |  | Ortho ( $\mathrm{N}=19$ ) |  |  |  |  |  |  |  |  |  |  |
| Cell Marker (Population) | CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status** | H | H | H | H | M | L | L | M | N | N | N | N | H | H | H | H | H | H |
| CD45+ | NA | 100 | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | NA |
| CD14+ | NA | 100 | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | NA |
| CD3+CD4+ | NA | 100 | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 33 | 100 | 100 | NA | 100 | 100 | 50 | NA |
| CD3+CD8+ | NA | 100 | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | NA | 50 | 100 | 100 | NA |
| CD3-CD19+ | NA | 100 | NA | NA | NA | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | NA |
| CD3-(CD56 \& CD16)+ | NA | 100 | NA | NA | NA | 100 | NA | NA | NA | 100 | 100 | NA | 100 | NA | 100 | NA | NA | NA |
| CD3+Average | NA | 100 | NA | NA | 100 | 700 | 100 | NA | 100 | 100 | 100 | 100 | 100 | NA | 75 | 100 | 100 | NA |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
NA = no data retumed by any laboratory for specified marker

| Cell Marker (Population) | Becto <br> Donor Number <br> $38 \quad 3940$ |  |  | ckinson ( $\mathrm{N}=121$ ) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |
|  |  |  |  | 42 | 43 | 44 | 45 |
| HIV Status** | L | L | L | N | N | N | N |
| CD45+ | 90 | 100 | 100 | 92 | 91 | 93 | 100 |
| CD14+ | 100 | 100 | 100 | 96 | 95 | 93 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 96 | 100 | 86 | 100 |
| CD3+CD8+ | 100 | 100 | 100 | 88 | 91 | 93 | 100 |
| CD3-CD19+ | 71 | 100 | 100 | 95 | 94 | 92 | 100 |
| CD3-(CD56 \& CD16)- | 33 | 100 | 100 | 95 | 93 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | 83 | 95 | 92 | 100 |



*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Deteminations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
$N A=$ no data retumed by any laboratory for specified marker

Table 5. Frequency of laboratory results for the Oc tober 1994 instrument performance control sample within, above, or below the $90 \%$ reference ranges*

Event Population

| Green Unsta ined Orange/Red Unstained |  | Green Stained Orange/Red Unstained |  | Green Unstained Orange/Red Stained |  | Green Stained Orange/Red Stained |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Range | Frequency | Range | Frequency | Range | Frequency | Range | Frequency |
| >25 |  | >21 | 8 | >23 | 7 | >22 | 8 |
| 25-30 | 252 | 21-27 | 252 | 23-27 | 251 | 22-26 | 247 |
| $>30$ | 9 | $>27$ | 7 | $>27$ | 9 | $>26$ | 12 |

*The $90 \%$ reference ranges were determined from results from the same laboratories whose results were used to determine the $90 \%$ reference ranges for Ta ble 1 .

Table 6. Frequency of 3-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -
Cell Marker


| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | 7 - | H | 8 | L | 9 | L | 10 | L | 11 | L | 12 - | N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
|  | > 39 | 0 | > 3 | 0 | > 3 | 0 | > 17 | 0 | > 13 | 0 | $>56$ | 0 |
|  | 31-39 | 2 | 1-3 | 2 | 1-3 | 1 | 10-17 | 1 | 9-13 | 1 | 48-56 | 2 |
|  | < 31 | 0 | $<1$ | 0 | $<1$ | 0 | $<10$ | 0 | $<9$ | 0 | < 48 | 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | > 39 | 0 | > 3 | 0 | > 3 | 0 | > 17 | 0 | > 13 | 0 | > 56 | 1 |
|  | $31-39$ | 4 | 1-3 | 3 | $1-3$ | 5 | 10-17 | 2 | 9-13 | 2 | 48-56 | 4 |
|  | < 31 | 0 | $<1$ | 0 | $<1$ | 0 | < 10 | 0 | $<9$ | 0 | < 48 | 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $>50$ | 0 | $>50$ | 0 | > 58 | 0 | > 50 | 0 | > 50 | 0 | > 27 | 0 |
|  | 39-50 | 2 | 30-50 | 1 | 49-58 | 1 | 33-50 | 1 | 40-50 | 1 | 21-27 | 1 |
|  | < 39 | 0 | $<30$ | 0 | < 49 | 0 | $<33$ | 0 | $<40$ | 0 | $<21$ | 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | > 50 | 0 | > 50 | 0 | > 58 | 1 | > 50 | 0 | > 50 | 0 | > 27 | 0 |
|  | 39-50 | 3 | 30-50 | 3 | 49-58 | 3 | 33-50 | 2 | 40-50 | 2 | $21-27$ | 4 |
|  | < 39 | 1 | < 30 | 0 | < 49 | 1 | $<33$ | 0 | $<40$ | 0 | < 21 | 1 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | > 12 | 0 | > 35 | 0 | $>34$ | 0 | > 11 | 0 | > 23 | 0 | $>13$ | 0 |
|  | $5-12$ | 2 | 24-35 | 1 | 27-34 | 1 | 6-11 | 1 | 17-23 | 1 | 7-13 | 1 |
|  | $<5$ | 0 | < 24 | 0 | $<27$ | 0 | $<6$ | 0 | $<17$ | 0 | $<7$ | 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $>9$ | 0 | $>23$ | 0 | $>14$ | 0 | > 35 | 0 | > 20 | 0 | $>16$ | 0 |
|  | 3-9 | 2 | 13-23 | 1 | 7-14 | 1 | 24-35 | 1 | 11-20 | 1 | 9-16 | 1 |
|  | $<3$ | 0 | < 13 | 0 | $<7$ | 0 | < 24 | 0 | < 11 | 0 | $<9$ | 0 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal a ntibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^3]Table 6. Frequency of 3-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -
Cell Marker

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelinesfor the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^4]Table 6. Frequency of 3-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -
Cell Marker

| (Population) | $28-\mathrm{N}$ |  | $29-N$ |  | $30-\mathrm{N}$ |  | $31-\mathrm{H}$ |  | $33-\mathrm{H}$ |  | $34-\mathrm{H}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{aligned} & \\ &>53 \\ & 42-53 \\ &<\end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \end{aligned}$ | $\begin{aligned} & \\ &>46 \\ & 41-46 \\ &<41\end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \\ &>69 \\ & 63-69 \\ &<63\end{aligned}$ | 0 <br> 2 <br> 1 | NA |  | NA |  | $\begin{aligned} & \\ & 32>41 \\ &-41 \\ &<32\end{aligned}$ | 0 4 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ |  $\begin{aligned} & >53 \\ & 42\end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | $\begin{aligned} & \\ &>46 \\ & 41-46 \\ &<41\end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & \\ &>69 \\ & 63-69 \\ &<63\end{aligned}$ | 1 0 1 0 | $\begin{array}{rl} \\ & > \\ 19 & 24 \\ & < \\ & < \\ \end{array}$ | 2 5 1 | $\begin{aligned} & \\ &>30 \\ & 23-30 \\ &<\end{aligned}$ | 0 2 2 | NA |  |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ |  $\begin{gathered}> \\ 16\end{gathered}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & \\ &>22 \\ & 15-22 \\ &<15\end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \end{aligned}$ | $\begin{aligned} & \\ &> \\ &> \\ & 18-21 \\ &<18\end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | NA |  | NA |  | $\begin{aligned} & \\ &>46 \\ & 33-46 \\ &< \\ &\end{aligned}$ | 0 2 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ |   <br>  $>$ <br>  $>$ <br> 16 -24 <br>   <br>   <br>  $<$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | $\begin{array}{rl} \\ & > \\ & \\ 15 & 22 \\ & \\ & <15\end{array}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \end{aligned}$ | $\begin{array}{rl} \\ & > \\ 18 & 21 \\ & -21 \\ & <18\end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \end{aligned}$ | $\begin{aligned} & \\ & \\ &>63 \\ & 51-63 \\ &< \\ &\end{aligned}$ | $\begin{aligned} & \hline 0 \\ & 7 \\ & 1 \\ & \hline \end{aligned}$ |   <br>  $>$ <br>   <br> 52 -63 <br>  $<$ <br>   | $\begin{aligned} & 0 \\ & 2 \\ & 2 \\ & \hline \end{aligned}$ | NA |  |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ |   <br>  $>$ <br>  $>16$ <br> 11 -16 <br>  $<$ <br>   <br>   | $\begin{aligned} & 1 \\ & 2 \\ & 0 \end{aligned}$ | NA |  | 6 6 | 0 2 0 | NA |  | NA |  | NA |  |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ |  $\begin{array}{r}14 \\ 10\end{array}$ | 0 1 2 | NA |  | $>88$ $4-8$ $<4$ | 0 2 0 | NA |  | NA |  | $>$ 2 2 -9 $<2$ | 0 2 0 |


| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | 35 | H | 36 | H | 38 | L | 39 | L | 40 | L | 42 - | N |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
|  | $>50$ | 0 | > 22 | 0 | $>2$ | 0 | > 2 | 0 | > 8 | 0 | > 29 | 0 |
|  | 40-50 | 2 | 18-22 | 2 | $0-2$ | 2 | $0-2$ | 1 | 5-8 | 2 | 17-29 | 2 |
|  | < 40 | 0 | < 18 | 2 | $<0$ | 0 | $<0$ | 0 | $<5$ | 0 | < 17 | 2 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $>50$ | 0 | > 22 | 4 | > 2 | 0 | $>2$ | 0 | $>8$ | 0 | > 29 | 1 |
|  | $40-50$ | 6 | 18-22 | 0 | 0-2 | 3 | $0-2$ | 3 | 5-8 | 5 | 17-29 | 6 |
|  | < 40 | 0 | < 18 | 2 | $<0$ | 0 | $<0$ | 0 | $<5$ | 0 | < 17 | 1 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | > 33 | 0 | > 74 | 0 | > 48 | 0 | $>60$ | 0 | > 81 | 0 | $>53$ | 0 |
|  | 23-33 | 2 | 67-74 | 2 | 36-48 | 1 | $54-60$ | 1 | 69-81 | 1 | 35-53 | 2 |
|  | < 23 | 0 | < 67 | 0 | < 36 | 0 | < 54 | 0 | < 69 | 0 | $<35$ | 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | > 33 | 1 | > 74 | 0 | > 48 | 1 | $>60$ | 0 | > 81 | 1 | $>53$ | 0 |
|  | 23-33 | 5 | 67-74 | 3 | 36-48 | 2 | $54-60$ | 2 | 69-81 | 4 | 35-53 | 6 |
|  | $<23$ | 0 | < 67 | 3 | < 36 | 0 | < 54 | 1 | < 69 | 0 | < 35 | 2 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $>14$ | 0 | $>6$ | 0 |  |  | $>30$ | 0 | > 12 | 0 | $>12$ | 0 |
|  | 10-14 | 4 | 3-6 | 4 | NA |  | 16-30 | 2 | 5-12 | 2 | $5-12$ | 1 |
|  | < 10 | 0 | < 3 | 0 |  |  | < 16 | 0 | < 5 | 0 | $<5$ | 1 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | > 9 | 0 | $>7$ | 1 | > 21 | 1 | $>12$ | 0 | $>7$ | 0 | $>20$ | 1 |
|  | 7-9 | 4 | 5-7 | 3 | 13-21 | 0 | 8-12 | 1 | 1-7 | 2 | 9-20 | 1 |
|  | $<7$ | 0 | $<5$ | 0 | < 13 | 0 | $<8$ | 1 | $<1$ | 0 | $<9$ | 1 |

*The $90 \%$ reference ranges were detemmined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^5]Table 6. Frequency of 3-color laboratory results for the September 1995 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

| Cell Marker (Population) | CDC DonorNumber HIV Status** |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 43 | N | 44 | N | 45 | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | > 47 | 0 |  |  | > 66 | 1 |
|  | 39-47 | 3 | NA |  | 55-66 | 1 |
|  | < 39 | 0 |  |  | < 55 | 1 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | > 47 | 2 | > 52 | 0 | > 66 | 1 |
|  | 39-47 | 5 | 46-52 | 1 | 55-66 | 5 |
|  | < 39 | 0 | < 46 | 0 | < 55 | 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | > 28 | 0 |  |  | > 27 | 0 |
|  | 22-28 | 2 | NA |  | 17-27 | 3 |
|  | < 22 | 0 |  |  | $<17$ | 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | > 28 | 1 | > 11 | 0 | > 27 | 0 |
|  | 22-28 | 5 | 8-11 | 0 | 17-27 | 6 |
|  | < 22 | 1 | < 8 | 1 | < 17 | 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | > 19 | 0 |  |  | > 13 | 0 |
|  | 13-19 | 2 | NA |  | 7-13 | 4 |
|  | < 13 | 0 |  |  | < 7 | 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | > 11 | 0 |  |  | $>6$ | 1 |
|  | 8-11 | 3 | NA |  | 3-6 | 3 |
|  | $<8$ | 0 |  |  | $<3$ | 0 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

${ }^{4}$ No. = frequency of laboratories $\quad N A=$ no data retumed by a ny la boratory for specified marker


[^0]:    ${ }^{\text {a }}$ Human immunodeficiency virus type 1

[^1]:    *The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
    **La boratories using Becton Dic kinson or Coulter monoc lonal antibodies exc lusively for all tests.
    *** HIV status: $\mathrm{N}=$ Negative; Positive --- L=Low CD4 ct ( $<200$ ), M $=$ Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$
    ****Results from laboratories using monoclonal a ntibodies from more than one manufacturer or from Dako, Caltag, GeI Immunotech, In-house, Ortho, Phamingen, or Sigma.
    NA = no data retumed by any laboratory for spec ified marker

[^2]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    $N A=$ no data retumed by any laboratory for specified marker

[^3]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    ${ }^{\Delta}$ No. = frequency of laboratories
    NA = no data retumed by any laboratory for specified marker

[^4]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    ${ }^{\Delta}$ No. = frequency of laboratories $\quad N A=$ no data retumed by a ny laboratory for specified marker

[^5]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    ${ }^{\Delta}$ No. = frequency of laboratories
    NA = no data retumed by any laboratory for specified marker

